Claims
- 1. A method of improving the active systemic humoral immune response in a mammal as measured by sheep red blood cell injection (SRBC), comprising administering orally to the mammal an effective amount of undenatured whey protein concentrate (WPC) obtained from bovine, goat or sheep milk and containing substantially all the whey protein present in the raw milk, administered as a daily replacement for up to all the protein consumed by the mammal, wherein the improved active systemic humoral immune response is based on the overall amino acid and associated small peptides pattern resulting from the contribution of substantially all of the WPC protein components, the daily amount of WPC not substantially exceeding the daily protein requirement for the mammal.
- 2. The method of claim 1, wherein the active systemic humoral immune response in the mammal is characterized by a dose-response pattern with relation to the amount of whey protein concentrate intake by the mammal.
- 3. The method of claim 1, wherein the improved active systemic humoral immune response is enhanced resistance to pneumococcal infection.
- 4. The method of claim 1, wherein the whey protein concentrate is undenatured bovine whey protein concentrate.
- 5. The method of claim 1, wherein the whey protein concentrate is a mixture of bovine, goat or sheep whey protein concentrate.
- 6. The method of claim 1, wherein the improved active systemic humoral immune response is associated with enhanced resistance of target cells against the mutagenic and carcinogenic effect of dimethylhydrozine.
- 7. The method of claim 1, wherein the active systemic humoral immune response is measured in splenic lymphocytes during the SRBC driven lymphocyte response.
- 8. The method of claim 1, wherein the whey protein concentrate has the amino acid composition of
- ______________________________________ WHEY PROTEINAMINO ACID CONCENTRATE______________________________________Phenylalanine 3.4 .+-. 0.3Tryptophan 2.1 .+-. 0.0Glycine 2.0 .+-. 0.2Serine 5.2 .+-. 0.4Leucine 10.4 .+-. 0.7Isoleucine 6.1 .+-. 0.8Valine 5.8 .+-. 0.8Methionine 2.1 .+-. 0.3Cysteine 2.3 .+-. 0.3Aspartic acid 10.7 .+-. 0.7Glutamic acid 18.8 .+-. 0.7Histidine 2.0 .+-. 0.2Tyrosine 3.0 .+-. 0.4Proline 6.1 .+-. 0.7Arginine 2.8 .+-. 0.3Alanine 4.9 .+-. 0.4Lysine 9.2 .+-. 0.5Threonine 6.8 .+-. 1.3______________________________________
- 9. The method of claim 1, which further comprises orally administering to the mammal about 1.2 to about 1.5 milligrams per day of vitamin B2.
- 10. The method of claim 1, which further comprises orally administering to the mammal about0.5 to 0.6 milligrams of vitamin B2 pre 1000 calorie per day.
- 11. The method of claim 1, which further comprises orally administering to the mammal about 0.5 milligrams per 1000 calorie of vitamin B1 per day.
- 12. The method of claim 1, which further comprises orally administering to the mammal vitamins B1 and B2 in amounts in excess of the minimum daily requirement for the mammal.
- 13. A method of producing a sustained increase of tissue concentration level of glutathione in a mammal, which comprises orally administering to the mammal an amount of undenatured whey protein concentrate obtained from bovine, goat or sheep milk and containing substantially all the whey protein present in the raw milk as a daily replacement for up to all the protein consumed by the mammal, wherein the sustained increase of the tissue concentration level of glutathione in the mammal is based on the overall amino acid and associated small peptides pattern resulting from the contribution of substantially all the WPC protein components, the daily amount of whey protein concentrate not substantially exceeding the daily protein requirement for the mammal.
- 14. The method of claim 13, wherein the sustained increase of tissue concentration level of glutathione in the mammal is characterized by a dose-response pattern with relation to the amount of whey protein concentrate intake by the mammal.
- 15. The method of claim 13, which further comprises orally administering to the mammal vitamin B2 in an amount of about 0.5 to 0.6 milligrams per 1000 calorie per day.
- 16. The method of claim 13, wherein the sustained increase of tissue concentration levels of glutathione in the mammal comprises an elevated level of glutathione above normal levels for at least three (3) months.
RELATED APPLICATION
This application is a continuation of U.S. application Ser. No. 289,971, filed Dec. 23, 1988, now abandoned, which is a continuation in part of U.S. application Ser. No. 188,271 filed Apr. 27, 1988, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4710387 |
Uiterwaal et al. |
Dec 1987 |
|
4753926 |
Lucas et al. |
Jun 1988 |
|
4784685 |
Meister |
Nov 1988 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
1136919 |
Jul 1982 |
CAX |
0022696 |
Jan 1981 |
EPX |
239722 |
Oct 1987 |
EPX |
2296428 |
Sep 1976 |
FRX |
WO874050 |
Jul 1987 |
WOX |
1495940 |
Dec 1977 |
GBX |
Non-Patent Literature Citations (5)
Entry |
Horwitt, M. K. in The Vitamins, 2d ed., vol. V, Academic Press, New York, 1972, pp. 88-96. |
Jansen, B. C. P. in The Vitamins, 2d ed., vol. V., Academic Press, New York, 1972, pp. 156-164. |
Bounous et al. J Nutr 112(9):1747-1755 (1982). |
Bounous et al. J Nutr 113:1415-1421 (1983). |
Bounous et al. J Nutr 115(11):1409-1417 (1985). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
289971 |
Dec 1988 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
188271 |
Apr 1988 |
|